Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Rosetta Stone: Pricing the 2009 IPO
Schill, Michael J.; Papireddy, Suprajj; Adams, Tom; Clough, PhilCaso DARDEN-F-1613-EFinanzasThis case examines the April 2009 decision of Rosetta Stone management to price the initial public offering of Rosetta Stone stock during one of the most difficult periods in capital-raising history. The case outlines Rosetta Stone’s unique language learning strategy and the associated strong financial performance. Students are invited to value the stock and take a position on whether the current $15 to $17 per share filing range is appropriate. ...Desde 8,20 €
-
Whole Foods Market: The Deutsche Bank Report - Teaching Note
Schill, Michael J.Nota del Instructor DARDEN-F-1776TN-EFinanzasTeaching note for product F-1776Desde 0,00 €
-
Teva Pharmaceuticals: Pricing the 2016 Bond Offering
Schill, Michael J.; Yates, AdamCaso DARDEN-F-2028-EFinanzasThis case examines the July 2016 decision by Israeli pharmaceutical Teva Pharmaceuticals Industries Limited (Teva) to raise USD19.5 billion in cash through a multicurrency bond offering to finance an acquisition that would firmly solidify Teva’s position as the largest generic pharmaceuticals manufacturer in the world. In light of a pending acquisition of Actavis, the generic drug manufacturing arm of Irish-US pharmaceutical Allergen Inc. (Allerg...Desde 8,20 €